(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.31%.
Tempest Therapeutics's earnings in 2024 is -$35,518,000.On average, 4 Wall Street analysts forecast TPST's earnings for 2024 to be -$60,553,375, with the lowest TPST earnings forecast at -$64,153,846, and the highest TPST earnings forecast at -$55,425,431. On average, 4 Wall Street analysts forecast TPST's earnings for 2025 to be -$45,715,070, with the lowest TPST earnings forecast at -$63,281,004, and the highest TPST earnings forecast at -$34,913,658.
In 2026, TPST is forecast to generate -$69,609,105 in earnings, with the lowest earnings forecast at -$92,521,193 and the highest earnings forecast at -$46,697,017.